Nutriband Inc. (NASDAQ: NTRB) has achieved a milestone in the pharmaceutical industry by securing U.S. patent No. 12,318,492 for its 'Abuse and Misuse Deterrent Transdermal Systems.' This patent, awarded on June 3, 2025, fortifies the company's intellectual property rights over its Aversa(TM) technology, designed to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure. The technology is pivotal in the development of Nutriband's lead product, Aversa Fentanyl, which aspires to be the first abuse-deterrent fentanyl patch available in the market, with potential U.S. sales ranging between $80 million and $200 million.
The significance of this patent extends beyond corporate achievement; it represents a critical advancement in public health. The opioid crisis has underscored the urgent need for innovative solutions to prevent drug abuse. Nutriband's Aversa(TM) technology, by making transdermal patches less susceptible to abuse, could play a vital role in curbing the epidemic, offering a safer alternative for patients requiring potent pain management solutions. This development not only enhances Nutriband's market position but also contributes to the broader effort to address one of the most pressing health challenges of our time.
